The stock may see modest positive sentiment on the enrollment milestone, but the real catalyst is the Q1 2027 data readout. Traders should monitor for any interim data updates or regulatory feedback that could shift the timeline. The long wait until data limits near-term upside.
Price Chart
Executive Summary
Dyne Therapeutics announced completion of enrollment in the registrational expansion cohort of the Phase 1/2 ACHIEVE trial for z-basivarsen in DM1, with topline data expected in Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027. This is a key clinical milestone for a company with no approved products, but the stock impact will depend on the actual data readout over a year away.
Key Facts
- Registrational expansion cohort of ACHIEVE trial fully enrolled with 71 participants
- Topline data from the cohort expected in Q1 2027
- Potential BLA submission for U.S. Accelerated Approval planned for Q3 2027
- Potential U.S. launch of z-basivarsen expected in H1 2028 if FDA grants Priority Review
- Z-basivarsen has Breakthrough Therapy, Orphan Drug, and Fast Track designations from FDA
- DM1 affects ~40,000 people in the U.S. and ~55,000 in the EU; no approved disease-modifying treatments exist
- Confirmatory Phase 3 HARMONIA trial is ongoing
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue
Risk Factors
- Topline data may fail to meet efficacy or safety endpoints, derailing approval prospects
- Regulatory pathway for Accelerated Approval is uncertain and subject to FDA discretion
- Competing therapies for DM1 could emerge before z-basivarsen reaches market
- Cash burn from ongoing trials without revenue may require future dilutive financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305941 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Insider Cluster | $26.15 $17.90 | ▲ +31.55% | ▲ +29.57% | $15.17 (+41.99%) |
Aug 14, 2026 6w ago | 144 | $26.15 $18.52 | ▼ −29.18% | ▼ −27.65% | $15.17 (−41.99%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▲ +27.94% | ▲ +25.95% | $15.17 (+40.97%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.17 (−40.97%) |
Aug 13, 2026 7w ago | 144 | $25.70 $18.52 | ▼ −27.94% | ▼ −25.95% | $15.17 (−40.97%) |
Jul 29, 2026 9w ago | Press Release | $25.73 $26.09 | ▲ +1.40% | ▼ −2.57% | $15.17 (−41.04%) |
Jul 22, 2026 10w ago | Press Release | $23.21 $26.78 | ▼ −15.38% | ▼ −12.48% | $15.17 (+34.64%) |
Jul 20, 2026 10w ago | 8-K | $23.45 $26.15 | ▲ +11.51% | ▲ +7.39% | $15.17 (−35.31%) |
Jun 30, 2026 13w ago | Insider Cluster | $21.79 $25.10 | ▲ +15.19% | ▲ +17.38% | $15.17 (−30.38%) |
Jun 29, 2026 13w ago | 144 | $22.21 $25.63 | ▼ −15.40% | ▼ −16.43% | $15.17 (+31.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access